Research and Development

At GMPO our research and development strategy is focused on the patient. Our mission is to identify and develop innovative therapies for patients, in the hope of making a meaningful difference to their lives.

We only work in rare diseases with an unmet medical need. There are over 7,000 known rare diseases. We have selected to develop our first product in Wilson Disease, a disease affecting 1 in every 30,000 of the population. Cuprior is an innovative formulation, that has the potential to offer new options to patients.

We have a network of world experts and work with scientists, academic institutions and companies with innovative technologies and products to enable their development and commercialization.

Cuprior Development

EU – Patients intolerant to D-Penicillamine
US – Patients intolerant to D-Penicillamine